Prostate-specific antitumor activity by probasin promoter-directed p202 expression

Area of Science:

• Oncology
• Molecular Biology
• Gene Therapy

Background:

• p202 is an interferon-inducible protein that inhibits cell cycle progression.
• Previous studies demonstrated p202's in vitro anti-prostate cancer effects.
• Prostate cancer cells expressing p202 exhibit reduced tumorigenicity and transformation potential.

Purpose of the Study:

• To evaluate the in vivo antitumor activity of p202 in prostate cancer.
• To develop a prostate-specific gene therapy approach for prostate cancer using p202.
• To investigate the molecular mechanisms underlying p202-mediated tumor suppression.

Main Methods:

• Stable expression of p202 in human prostate cancer cells.
• In vivo studies using mouse xenograft models (ex vivo and orthotopic).
• Development and systemic administration of a liposome-mediated gene delivery system (ARR2PB-p202).
• DNA microarray analysis to identify downstream molecular targets.

Main Results:

• Prostate cancer cells with stable p202 expression showed reduced tumorigenicity.
• Systemic administration of ARR2PB-p202/liposome complex resulted in prostate-specific p202 expression and significant tumor suppression in orthotopic models.
• p202 expression correlated with the downregulation of G2/M cell-cycle regulators, including cyclin B and p55cdc.

Conclusions:

• p202 effectively suppresses prostate tumor growth.
• Liposome-mediated, prostate-specific delivery of ARR2PB-p202 offers a potential therapeutic strategy for prostate cancer.
• p202 exerts its antitumor effects partly by downregulating key cell-cycle regulators.